|Bid||39.01 x 0|
|Ask||39.56 x 0|
|Day's Range||38.91 - 39.64|
|52 Week Range||29.69 - 41.06|
|Beta (5Y Monthly)||0.46|
|PE Ratio (TTM)||25.15|
|Earnings Date||Feb 14, 2020|
|Forward Dividend & Yield||0.96 (2.46%)|
|Ex-Dividend Date||Nov 18, 2019|
|1y Target Est||36.31|
Recordati announces that the European Commission has granted marketing authorisation for the orphan medicinal product Isturisa® (osilodrostat), indicated for the treatment of endogenous Cushing’s syndrome (CS) in adults. The active substance of Isturisa® is osilodrostat, a cortisol synthesis inhibitor.
Recordati announces that the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Isturisa®, indicated for the treatment of endogenous Cushing’s syndrome in adults. The benefits with Isturisa® are its ability to control or normalise raised cortisol levels. Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published in the European public assessment report (EPAR) and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.
RECORDATI ANNOUNCES GROWTH IN THE FIRST NINE MONTHS 2019. REVENUES +8.6%, EBITDA +7.8%, OPERATING INCOME +4.9%, NET INCOME +6.6%. INTERIM DIVIDEND € 0.48 (+6.7%). Consolidated.
Recordati announced the successful completion of the acquisition from Novartis of worldwide rights to Signifor® and Signifor® LAR® for the treatment of Cushing’s disease and acromegaly in adult patients for whom surgery is not an option or for whom surgery has failed, following the agreement signed on 12 July 2019. The acquisition also covers the worldwide rights to osilodrostat (LCI699), an investigational innovative drug for the treatment of endogenous Cushing’s syndrome, for which marketing authorization applications have been filed in the European Union and in the USA.
RECORDATI ANNOUNCES GROWTH IN THE FIRST HALF 2019. REVENUES +6.8%, EBITDA(1) +7.4%, NET INCOME +6.1% ·Consolidated revenues € 743.3 million, +6.8%.·EBITDA (1) € 279.3 million,.
Recordati announces the signing of an agreement with Novartis for the acquisition of worldwide rights to Signifor® and Signifor® LAR® for the treatment of Cushing’s disease and acromegaly in adult patients for whom surgery is not an option or for whom surgery has failed. Worldwide sales of Signifor® in 2018 were $ 72 million.
Recordati Rare Diseases, a worldwide leader in rare diseases and orphan drugs, today reported that its strategy aimed at establishing a direct presence in the key markets across all continents has been successfully executed. Local Recordati Rare Diseases companies are now active in North America, Latin America, Europe, MENA (Middle East and North Africa) and Asia Pacific.
Q1 2019 Recordati Industria Chimica e Farmaceutica SpA Earnings & 2019-2021 Business Plan Call
RECORDATI ANNOUNCES GROWTH IN THE FIRST QUARTER 2019. NEW THREE YEAR BUSINESS PLAN APPROVED. Consolidated revenues € 383.0 million, +4.5%.EBITDA (1) € 143.9 million,.
Recordati’s first quarter 2019 results and the Group’s development strategy and objectives for the period 2019-2021 will be presented at this meeting. Recordati is a partner of choice for new product licenses for its territories.
RECORDATI SHAREHOLDERS APPROVE THE 2018 ACCOUNTS. DIVIDEND € 0.92 PER SHARE (+8.2% vs 2017). Shareholders approve the 2018 results: consolidated revenues € 1,352.2 million.
RECORDATI: BOARD APPROVES THE 2018 ACCOUNTS. SALES € 1,352.2 MILLION (+5.0%), EBITDA € 499.1 MILLION (+9.8%), OPERATING INCOME € 442.2 MILLION (+8.8%) AND NET INCOME € 312.4.
RECORDATI: PRELIMINARY 2018 RESULTS CONFIRM CONTINUED GROWTH OF SALES AND PROFITABILITY. SALES +5.0%, EBITDA +9.8%, OPERATING INCOME +8.8%, NET INCOME +8.2%. Consolidated.
Recordati announces the signing of a license agreement with Aegerion Pharmaceuticals Inc., a subsidiary of Novelion Therapeutics Inc., for the exclusive rights to commercialize Juxtapid®, currently approved for the treatment of homozygous familial hypercholesterolemia (HoFH), in Japan. The agreement includes a right of first negotiation for product commercialization in Japan of any potential new indications that may be developed by Aegerion. Upon signing of the agreement an upfront payment of $ 25 million is due to Aegerion, in addition to a near term milestone of $ 5 million.
Italian drugmaker Zambon is looking to China and the U.S. to grow its respiratory and nervous system portfolio and could spend more than 100 million euros ($114 million) on the right acquisition, its chief executive said. The family-owned pharma group, famous for its mucolytic agent Fluimucil, used to treat respiratory problems, has cash enough to fund expansion plans but could contemplate a stock market listing if a big opportunity arose. "It's not on the table at the moment, but we could consider it if a large-scale project comes along," Roberto Tascione told Reuters in an interview.